 REDWOOD CITY, Calif., July 07, 2021 GLOBE NEWSWIRE -- Codexis, Inc. Nasdaq: CDXS, a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver protein engineering platform technology to GlaxoSmithKline GSK. This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter. 